Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2019 Jun 10;35(6):950-952. doi: 10.1016/j.ccell.2019.05.012. No abstract available.

2.

DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.

Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS.

Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.

3.

Fluoromethylcyclopropylamine derivatives as potential in vivo toxicophores - A cautionary disclosure.

Acton B, Small HF, Smith KM, McGonagle A, Stowell AIJ, James DI, Hamilton NM, Hamilton N, Hitchin JR, Hutton CP, Waddell ID, Ogilvie DJ, Jordan AM.

Bioorg Med Chem Lett. 2019 Feb 15;29(4):560-562. doi: 10.1016/j.bmcl.2018.12.066. Epub 2019 Jan 2.

4.

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides.

Waszkowycz B, Smith KM, McGonagle AE, Jordan AM, Acton B, Fairweather EE, Griffiths LA, Hamilton NM, Hamilton NS, Hitchin JR, Hutton CP, James DI, Jones CD, Jones S, Mould DP, Small HF, Stowell AIJ, Tucker JA, Waddell ID, Ogilvie DJ.

J Med Chem. 2018 Dec 13;61(23):10767-10792. doi: 10.1021/acs.jmedchem.8b01407. Epub 2018 Nov 19.

PMID:
30403352
5.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):950-952.

6.

Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1.

Mould DP, Bremberg U, Jordan AM, Geitmann M, McGonagle AE, Somervaille TCP, Spencer GJ, Ogilvie DJ.

Bioorg Med Chem Lett. 2017 Oct 15;27(20):4755-4759. doi: 10.1016/j.bmcl.2017.08.052. Epub 2017 Aug 24.

PMID:
28927796
7.

An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells.

James DI, Durant S, Eckersley K, Fairweather E, Griffiths LA, Hamilton N, Kelly P, O'Connor M, Shea K, Waddell ID, Ogilvie DJ.

Version 2. F1000Res. 2016 Apr 25 [revised 2016 Jan 1];5:736. eCollection 2016.

8.

IncucyteDRC: An R package for the dose response analysis of live cell imaging data.

Chapman PJ, James DI, Watson AJ, Hopkins GV, Waddell ID, Ogilvie DJ.

F1000Res. 2016 May 23;5:962. eCollection 2016.

9.

First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib.

James DI, Smith KM, Jordan AM, Fairweather EE, Griffiths LA, Hamilton NS, Hitchin JR, Hutton CP, Jones S, Kelly P, McGonagle AE, Small H, Stowell AI, Tucker J, Waddell ID, Waszkowycz B, Ogilvie DJ.

ACS Chem Biol. 2016 Nov 18;11(11):3179-3190. Epub 2016 Oct 12.

PMID:
27689388
10.

Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.

Watson AJ, Hopkins GV, Hitchin S, Begum H, Jones S, Jordan A, Holt S, March HN, Newton R, Small H, Stowell A, Waddell ID, Waszkowycz B, Ogilvie DJ.

Version 2. F1000Res. 2016 May 26 [revised 2016 Jan 1];5:1005. doi: 10.12688/f1000research.8724.2. eCollection 2016.

11.

Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2.

Hornyak P, Askwith T, Walker S, Komulainen E, Paradowski M, Pennicott LE, Bartlett EJ, Brissett NC, Raoof A, Watson M, Jordan AM, Ogilvie DJ, Ward SE, Atack JR, Pearl LH, Caldecott KW, Oliver AW.

Biochem J. 2016 Jul 1;473(13):1869-79. doi: 10.1042/BCJ20160180. Epub 2016 Apr 20.

12.

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.

Jordan AM, Begum H, Fairweather E, Fritzl S, Goldberg K, Hopkins GV, Hamilton NM, Lyons AJ, March HN, Newton R, Small HF, Vishwanath S, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2724-9. doi: 10.1016/j.bmcl.2016.03.100. Epub 2016 Mar 30.

13.

A high-throughput screening-compatible homogeneous time-resolved fluorescence assay measuring the glycohydrolase activity of human poly(ADP-ribose) glycohydrolase.

Stowell AI, James DI, Waddell ID, Bennett N, Truman C, Hardern IM, Ogilvie DJ.

Anal Biochem. 2016 Jun 15;503:58-64. doi: 10.1016/j.ab.2016.03.016. Epub 2016 Mar 29.

PMID:
27036617
14.

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.

Newton R, Bowler KA, Burns EM, Chapman PJ, Fairweather EE, Fritzl SJR, Goldberg KM, Hamilton NM, Holt SV, Hopkins GV, Jones SD, Jordan AM, Lyons AJ, Nikki March H, McDonald NQ, Maguire LA, Mould DP, Purkiss AG, Small HF, Stowell AIJ, Thomson GJ, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

Eur J Med Chem. 2016 Apr 13;112:20-32. doi: 10.1016/j.ejmech.2016.01.039. Epub 2016 Jan 29.

15.

Rethinking 'academic' drug discovery: the Manchester Institute perspective.

Jordan AM, Waddell ID, Ogilvie DJ.

Drug Discov Today. 2015 May;20(5):525-35. doi: 10.1016/j.drudis.2014.12.011. Epub 2014 Dec 24. Review.

PMID:
25542353
16.

Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment.

Wiseman DH, Small HF, Wilks DP, Waddell ID, Dennis MW, Ogilvie DJ, Somervaille TC.

Br J Haematol. 2014 Jul;166(1):145-8. doi: 10.1111/bjh.12826. Epub 2014 Mar 10. No abstract available.

PMID:
24606602
17.

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.

Raoof A, Depledge P, Hamilton NM, Hamilton NS, Hitchin JR, Hopkins GV, Jordan AM, Maguire LA, McGonagle AE, Mould DP, Rushbrooke M, Small HF, Smith KM, Thomson GJ, Turlais F, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

J Med Chem. 2013 Aug 22;56(16):6352-70. doi: 10.1021/jm400568p. Epub 2013 Jul 31.

PMID:
23859074
18.

A fluorescence-based assay for the apurinic/apyrimidinic-site cleavage activity of human tyrosyl-DNA phosphodiesterase 1.

Thomson GJ, Hamilton NS, Hopkins GV, Waddell ID, Watson AJ, Ogilvie DJ.

Anal Biochem. 2013 Sep 1;440(1):1-5. doi: 10.1016/j.ab.2013.05.003. Epub 2013 May 18.

PMID:
23688965
19.

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.

Kendrew J, Odedra R, Logié A, Taylor PJ, Pearsall S, Ogilvie DJ, Wedge SR, Jürgensmeier JM.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1021-32. doi: 10.1007/s00280-013-2097-x. Epub 2013 Jan 26.

PMID:
23355042
20.

Novel steroid inhibitors of glucose 6-phosphate dehydrogenase.

Hamilton NM, Dawson M, Fairweather EE, Hamilton NS, Hitchin JR, James DI, Jones SD, Jordan AM, Lyons AJ, Small HF, Thomson GJ, Waddell ID, Ogilvie DJ.

J Med Chem. 2012 May 10;55(9):4431-45. doi: 10.1021/jm300317k. Epub 2012 Apr 27.

PMID:
22506561
21.

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.

Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, Miller CJ, Ogilvie DJ, Somervaille TC.

Cancer Cell. 2012 Apr 17;21(4):473-87. doi: 10.1016/j.ccr.2012.03.014. Epub 2012 Mar 29. Erratum in: Cancer Cell. 2012 Jun 12;21(6):856.

22.

Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.

Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25.

23.
24.

Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

Barlaam B, Acton DG, Ballard P, Bradbury RH, Cross D, Ducray R, Germain H, Hudson K, Klinowska T, Magnien F, Ogilvie DJ, Olivier A, Ross HS, Smith R, Trigwell CB, Vautier M, Wright L.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1799-803. doi: 10.1016/j.bmcl.2008.02.035. Epub 2008 Feb 16.

PMID:
18313293
25.

Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.

Ducray R, Ballard P, Barlaam BC, Hickinson MD, Kettle JG, Ogilvie DJ, Trigwell CB.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):959-62. doi: 10.1016/j.bmcl.2007.12.035. Epub 2007 Dec 23.

PMID:
18182285
26.

A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

Barlaam B, Ballard P, Bradbury RH, Ducray R, Germain H, Hickinson DM, Hudson K, Kettle JG, Klinowska T, Magnien F, Ogilvie DJ, Olivier A, Pearson SE, Scott JS, Suleman A, Trigwell CB, Vautier M, Whittaker RD, Wood R.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):674-8. Epub 2007 Nov 21.

PMID:
18061446
27.

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

Ballard P, Barlaam BC, Bradbury RH, Dishington A, Hennequin LF, Hickinson DM, Hollingsworth IM, Kettle JG, Klinowska T, Ogilvie DJ, Pearson SE, Scott JS, Suleman A, Whittaker R, Williams EJ, Wood R, Wright L.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6326-9. Epub 2007 Sep 2.

PMID:
17869514
28.

Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Kettle JG, Kendrew J, Klinowska T, Ogilvie DJ, Pearson SE, Williams EJ, Wilson I.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4908-12. Epub 2006 Jun 27.

PMID:
16806916
29.

Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.

Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Johnson PD, Kettle JG, Klinowska T, Leach AG, Morgentin R, Pass M, Ogilvie DJ, Olivier A, Warin N, Williams EJ.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1633-7. Epub 2005 Dec 27.

PMID:
16380259
30.

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.

Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Johnson PD, Kettle JG, Klinowska T, Morgentin R, Ogilvie DJ, Olivier A.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4226-9.

PMID:
16055332
31.

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ.

Cancer Res. 2005 May 15;65(10):4389-400.

32.

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.

Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Esser N.

Angiogenesis. 2004;7(4):347-54. Epub 2005 May 9.

PMID:
15886878
33.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF.

Cancer Res. 2002 Aug 15;62(16):4645-55.

34.

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.

J Med Chem. 2002 Mar 14;45(6):1300-12.

PMID:
11881999
35.

Inhibition of VEGF signal transduction. Identification of ZD4190.

Wedge SR, Ogilvie DJ.

Adv Exp Med Biol. 2000;476:307-10. No abstract available.

PMID:
10949675
36.

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF.

Cancer Res. 2000 Feb 15;60(4):970-5.

37.

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C.

J Med Chem. 1999 Dec 30;42(26):5369-89.

PMID:
10639280
38.
39.

End rescue from YACs using the vectorette.

Ogilvie DJ, James LA.

Methods Mol Biol. 1996;54:131-8. No abstract available.

PMID:
8597785
40.

Yeast artificial chromosome cloning of the beta-catenin locus on human chromosome 3p21-22.

Bailey A, Norris AL, Leek JP, Clissold PM, Carr IM, Ogilvie DJ, Morrison JF, Meredith DM, Markham AF.

Chromosome Res. 1995 May;3(3):201-3.

PMID:
7780664
41.

No evidence for involvement of type 1 collagen structural genes in 'genetic predisposition' to alcoholic cirrhosis.

Bashir R, Day CP, James OF, Ogilvie DJ, Sykes B, Bassendine MF.

J Hepatol. 1992 Nov;16(3):316-9.

PMID:
1362577
42.

Walking, cloning, and mapping with yeast artificial chromosomes: a contig encompassing D21S13 and D21S16.

Butler R, Ogilvie DJ, Elvin P, Riley JH, Finniear RS, Slynn G, Morten JE, Markham AF, Anand R.

Genomics. 1992 Jan;12(1):42-51.

PMID:
1733862
43.

Segregation of structural collagen genes in adolescent idiopathic scoliosis.

Carr AJ, Ogilvie DJ, Wordsworth BP, Priestly LM, Smith R, Sykes B.

Clin Orthop Relat Res. 1992 Jan;(274):305-10.

PMID:
1345899
44.

Two sequence-tagged sites defining the ends of a 380 kb YAC clone from 19q13.

Butler R, Riley JH, Ogilvie DJ, Anand R, Buxton J, Davies J, Johnson K, Markham AF.

Nucleic Acids Res. 1991 Sep 11;19(17):4787. No abstract available.

46.

A yeast artificial chromosome contig encompassing the cystic fibrosis locus.

Anand R, Ogilvie DJ, Butler R, Riley JH, Finniear RS, Powell SJ, Smith JC, Markham AF.

Genomics. 1991 Jan;9(1):124-30.

PMID:
1706309
47.

Segregation of all four major fibrillar collagen genes in the Marfan syndrome.

Ogilvie DJ, Wordsworth BP, Priestley LM, Dalgleish R, Schmidtke J, Zoll B, Sykes BC.

Am J Hum Genet. 1987 Dec;41(6):1071-82.

48.

An RFLP close to the human collagen I gene COL1A1.

Ogilvie DJ, Aitchison K, Sykes BC.

Nucleic Acids Res. 1987 Jun 11;15(11):4699. No abstract available.

49.
50.

Collagenase secretion by human breast neoplasms: a clinicopathologic investigation.

Ogilvie DJ, Hailey JA, Juacaba SF, Lee EC, Tarin D.

J Natl Cancer Inst. 1985 Jan;74(1):19-27.

PMID:
2982053

Supplemental Content

Loading ...
Support Center